Cardiology Today Current Issue

The following articles appeared in the print edition of Cardiology Today.

Table of Contents

• Experts consider CV implications of SGLT2 inhibitors Erik Swain
• The current state of management and treatment options for resistant hypertension John B. Kostis, MD
• New hypertension guidelines generate discussion among medical community
• Predictions for cardiologists in the changing health care landscape L. Samuel Wann, MD, MACC, FESC
• FDA advisory panel recommends against approval of cangrelor for two indications
• Daiichi Sankyo seeks FDA approval for Savaysa
• FDA advisers: Data do not support lower CV risk with naproxen
• Surgeon General report identifies more health hazards from smoking
• Testosterone therapy under fire for possible link to CV events
• AAA screening could improve outcomes for elderly men
• Evaluation rates for PAD before amputation low
• Many Americans consume more added sugar than recommended for a healthy diet
• Many cardiac implantable device models approved without new clinical data
• MI survival rates higher in Sweden than UK
• Office, clinic visits for angina declined since 1995
• Lower-intensity statin combination potential alternative to monotherapy
• Transfer rates vary after admission for acute MI at nonprocedure hospitals
• Warfarin initiation increased stroke risk within 30 days of use
• Age, stroke severity not factors in effectiveness of tPA
• Common infection linked to ischemic stroke in children
• CRYSTAL AF: Insertable cardiac monitor detected AF in patients with cryptogenic stroke
• Risk for thrombotic events may persist for 12 weeks after delivery
• TAVR proliferation linked to better outcomes, more options for patients
• CRYSTAL AF
• DECAAF
• HYPITAT-II
• LEVANT I
• PRONTO
• STROLL
• URICO-ICTUS
• VIPS